Recent developments in pharmacophore-based modeling of Ca <sup>2+/</sup> Calmodulin-dependent protein kinase II delta (CaMkIIδ) inhibitors for heart failure therapy
Pharmacophore-driven CaMKIIδ modeling remains underused. Progress should integrate AI/deep learning, isoform-aware selectivity filters, state- and PTM-specific targeting, and rigorous experimental validation to deliver potent, selective, clinically viable inhibitors for heart failure. Standardized benchmarking, transparent negative results, and selectivity panels against CaMKIIα/β/γ and kinome off-targets will aid translation substantially.
Authors
- Mutasem O. Taha (ORCID: https://orcid.org/0000-0002-4453-072X)
- Safa Dauod
Institutions
- University of Jordan (JO)
- Applied Science Private University (JO)
Publication Details
- Journal
- Expert Opinion on Drug Discovery
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1080/17460441.2026.2643408
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 0.00